Back to search

Sweden· SE-20231009000225

Hympavzi 150 mg Injektionsvätska, lösning i förfylld injektionspenna

A medicinal product containing marstacimab, registered in Sweden by Pfizer Europe MA EEIG.

Checked against Swedish Medical Products Agency (Sweden) on

Informational only — not a medical device.

SOURCE REGISTER · SESwedish Medical Products Agency (Sweden)normalisedHympavzi 150 mg Injektionsvätska, lös…ATC—REGISTER NO.SE-20231009000225PACKS LISTED1CHECKEDOctober 1, 2026

The record

At a glance

Swedish Medical Products Agency (Sweden)
Active substance
Marstacimab
Manufacturer
Pfizer Europe MA EEIG
Country
Sweden (SE)
ATC code
—
Reimbursed
Not published by this register
Source register
Swedish Medical Products Agency (Sweden)
Last checked
October 1, 2026

Packs & prices · 1

  • se_varunummer
    20231009000225

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Marstacimab in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All marstacimab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Hympavzi
  • Liechtenstein · Hympavzi
  • Norway · Hympavzi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/8bedec50-4ae1-40a6-84ec-5277ae6b5e85
GET /v1/drugs/8bedec50-4ae1-40a6-84ec-5277ae6b5e85?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "source": "lakemedelsverket",
  "doc_types": [
    "EPAR",
    "EMA"
  ],
  "se_npl_id": "20231009000225",
  "product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20231009000225",
  "product_doc_link": "https://www.ema.europa.eu/sv/documents/product-information/hympavzi-epar-product-information_sv.pdf"
}

See everything about marstacimab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.